JP2023524291A5 - - Google Patents

Info

Publication number
JP2023524291A5
JP2023524291A5 JP2022567079A JP2022567079A JP2023524291A5 JP 2023524291 A5 JP2023524291 A5 JP 2023524291A5 JP 2022567079 A JP2022567079 A JP 2022567079A JP 2022567079 A JP2022567079 A JP 2022567079A JP 2023524291 A5 JP2023524291 A5 JP 2023524291A5
Authority
JP
Japan
Prior art keywords
aav
item
vector
vector according
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524291A (ja
JP7756439B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030937 external-priority patent/WO2021226267A2/en
Publication of JP2023524291A publication Critical patent/JP2023524291A/ja
Publication of JP2023524291A5 publication Critical patent/JP2023524291A5/ja
Application granted granted Critical
Publication of JP7756439B2 publication Critical patent/JP7756439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567079A 2020-05-05 2021-05-05 異種間適合性アデノ随伴ウイルス組成物およびその使用方法 Active JP7756439B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05
US63/020,062 2020-05-05
PCT/US2021/030937 WO2021226267A2 (en) 2020-05-05 2021-05-05 Cross-species compatible adeno-associated virus compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023524291A JP2023524291A (ja) 2023-06-09
JP2023524291A5 true JP2023524291A5 (enExample) 2024-05-15
JP7756439B2 JP7756439B2 (ja) 2025-10-20

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567079A Active JP7756439B2 (ja) 2020-05-05 2021-05-05 異種間適合性アデノ随伴ウイルス組成物およびその使用方法

Country Status (13)

Country Link
US (3) US12577586B2 (enExample)
EP (1) EP4125977A4 (enExample)
JP (1) JP7756439B2 (enExample)
KR (1) KR20230029616A (enExample)
CN (1) CN116096377B (enExample)
AR (1) AR122013A1 (enExample)
AU (1) AU2021268946A1 (enExample)
BR (1) BR112022022644A2 (enExample)
CA (1) CA3177869A1 (enExample)
IL (1) IL297577A (enExample)
MX (1) MX2022013963A (enExample)
TW (1) TWI910162B (enExample)
WO (1) WO2021226267A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013963A (es) * 2020-05-05 2023-02-22 Univ Duke Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
EP4413147A4 (en) 2021-10-08 2025-07-30 Dyno Therapeutics Inc CAPSID VARIANTS AND METHODS OF USE THEREOF
US20260055144A1 (en) * 2022-08-24 2026-02-26 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024168089A2 (en) * 2023-02-07 2024-08-15 Duke University Compositions comprising aavs and methods for treating gastrointestinal diseases
TW202434734A (zh) * 2023-02-08 2024-09-01 美商銀杏生物工作室有限公司 天使症候群的基因療法
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2024206831A1 (en) * 2023-03-31 2024-10-03 Duke University Compositions comprising brain-tropic aavs and methods of use thereof
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
HUE054805T2 (hu) 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US9409953B2 (en) * 2011-02-10 2016-08-09 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
CN105247044B (zh) * 2013-05-31 2021-05-07 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
IL314171A (en) * 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
CA3052829A1 (en) 2017-02-15 2018-08-23 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
CN110650733A (zh) 2017-02-28 2020-01-03 阿德夫拉姆生物技术股份有限公司 经过修饰的aav衣壳和其用途
US11332727B2 (en) 2017-03-14 2022-05-17 The Regents Of The University Of California Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
IL316259A (en) 2017-03-15 2024-12-01 Univ North Carolina Chapel Hill Polyploid gland associated with virus vectors and methods for preparing and using the same.
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019195444A1 (en) * 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
BR112021006060A2 (pt) * 2018-10-01 2021-07-20 The Trustees Of The University Of Pennsylvania composições úteis para tratamento de gangliosidose gm1
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
MX2022013963A (es) 2020-05-05 2023-02-22 Univ Duke Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.

Similar Documents

Publication Publication Date Title
JP7707261B2 (ja) 筋疾患の治療のための改変aavカプシドポリペプチド
JP2026027271A5 (enExample)
JP2022530633A5 (enExample)
JP2022526018A5 (enExample)
JP2022530656A5 (enExample)
JP2022530544A5 (enExample)
AU2017235333A1 (en) CRISPR/CAS-related methods and compositions for treating beta hemoglobinopathies
WO2004020600A2 (en) Modified aav
RU2751592C2 (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
JP2022530824A5 (enExample)
JP2022501060A5 (enExample)
TW201629225A (zh) 第九因子基因療法
JP2022531861A5 (enExample)
US20220380798A1 (en) AAV Expression Cassette and AAV Vectors Comprising the Same
JP2021531044A5 (enExample)
JP2021500070A5 (enExample)
CN121219423A (zh) 工程化血脑屏障穿透型aav衣壳
JP2025513066A5 (enExample)
CN119403823A (zh) 具有增强的肌肉转导效率的肽修饰的aav衣壳
CA3271456A1 (en) AAVS RECOMMENDATIONS WITH IMPROVED TROPISM AND SPECIFICITY
JP2022512589A5 (enExample)
JP2022525848A5 (enExample)
JP2024515902A5 (enExample)
WO2021230385A1 (en) Method for treating muscular dystrophy by targeting utrophin gene